These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11677931)

  • 1. Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance.
    Lu J; Gries JM; Verotta D; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2001 Aug; 28(4):343-62. PubMed ID: 11677931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of population pharmacokinetic parameters in the presence of non-compliance.
    Mu S; Ludden TM
    J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):53-81. PubMed ID: 12800807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria.
    Kshirsagar SA; Blaschke TF; Sheiner LB; Krygowski M; Acosta EP; Verotta D
    J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):35-55. PubMed ID: 17004125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population one-compartment pharmacokinetic analysis with missing dosage data.
    Soy D; Beal SL; Sheiner LB
    Clin Pharmacol Ther; 2004 Nov; 76(5):441-51. PubMed ID: 15536459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.
    Hashimoto Y; Sheiner LB
    J Pharmacokinet Biopharm; 1991 Jun; 19(3):333-53. PubMed ID: 1875286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An alternative method for population pharmacokinetic data analysis under noncompliance.
    Gupta P; Hutmacher MM; Frame B; Miller R
    J Pharmacokinet Pharmacodyn; 2008 Apr; 35(2):219-33. PubMed ID: 18299967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.
    Cota JM; FakhriRavari A; Rowan MP; Chung KK; Murray CK; Akers KS
    Clin Ther; 2016 Sep; 38(9):2016-31. PubMed ID: 27586127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of compliance in pharmacokinetic studies.
    Vrijens B; Goetghebeur E
    Stat Methods Med Res; 1999 Sep; 8(3):247-62. PubMed ID: 10636337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying the Effectiveness of Dose Individualization by Simulation for a Drug With Moderate Pharmacokinetic Variability.
    Liefaard L; Chen C
    Ther Drug Monit; 2015 Oct; 37(5):641-8. PubMed ID: 26378372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
    Fabre MA; Fuseau E; Ficheux H
    J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of some control strategies for three-compartment PK/PD models.
    Hu C; Lovejoy WS; Shafer SL
    J Pharmacokinet Biopharm; 1994 Dec; 22(6):525-50. PubMed ID: 7473080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies.
    Vrijens B; Goetghebeur E
    Stat Med; 2004 Feb; 23(4):531-44. PubMed ID: 14755387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of population D-optimal designs via pharmacokinetic simulations.
    Hooker AC; Foracchia M; Dodds MG; Vicini P
    Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PK-DB: pharmacokinetics database for individualized and stratified computational modeling.
    Grzegorzewski J; Brandhorst J; Green K; Eleftheriadou D; Duport Y; Barthorscht F; Köller A; Ke DYJ; De Angelis S; König M
    Nucleic Acids Res; 2021 Jan; 49(D1):D1358-D1364. PubMed ID: 33151297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.
    Slavik RS; Jewesson PJ
    Clin Pharmacokinet; 2003; 42(9):793-817. PubMed ID: 12882587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds.
    Pelekis M; Gephart LA; Lerman SE
    Regul Toxicol Pharmacol; 2001 Feb; 33(1):12-20. PubMed ID: 11259175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
    Bellissant E; Courcier-Duplantier S; Blin O;
    Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
    Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
    Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.